Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-11 of 11 for your search:
Cancer Type/Condition:
Childhood germ cell tumor
Stage/Subtype:
recurrent childhood germ cell tumor
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
BMT 0499 Solid
, NCT00179816
2.
Evaluation of Single Session Stereotactic Body Radiotherapy
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
2005-0445
, NCT00492817
3.
Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)
Phase:
Phase II, Phase I
Type:
Supportive care, Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
ID02-446
, NCT00508443
4.
Phase I/II Study of Dasatinib in Combination With Ifosfamide, Carboplatin, and Etoposide Phosphate in Young Patients With Metastatic or Recurrent Malignant Solid Tumors
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 25
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
CHNMC-07053
, 07053, CA180 121, NCT00788125
5.
Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 30
Sponsor:
Other
Protocol IDs:
OHSU-5056
, OHSU SOL-08131-L, NCT00983398
6.
Phase II Study of Paclitaxel, Ifosfamide, and Carboplatin in Pediatric Patients With Recurrent or Resistant Malignant Germ Cell Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Under 21 at original diagnosis
Sponsor:
NCI
Protocol IDs:
COG-AGCT0521
, AGCT0521, NCT00467051
7.
High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
12 to 65
Sponsor:
Other
Protocol IDs:
2008-0378
, NCT00936936
8.
Phase I Study of Ixabepilone in Young Patients With Refractory Solid Tumors (Closed to Accrual as of 10/4/2007) or Relapsed or Refractory Leukemia
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
2 to 21
Sponsor:
NCI
Protocol IDs:
NCI-02-C-0031
, 02-C-0031, 5425, NCI-5425, NCT00030108
9.
Phase I Study of Cediranib in Pediatric Patients With Refractory or Recurrent Extracranial Malignant Solid Tumors or Acute Myeloid Leukemia
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
2 to 18
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
NCI-06-C-0152
, NCI-P6571, NCT00354848, ZENECA-D8480C00016
10.
Phase I Study of Trabectedin in Pediatric Patients With Relapsed or Refractory Solid Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
4 to 16
Sponsor:
NCI
Protocol IDs:
NCI-07-C-0054
, NCT00437047
11.
Pilot Study of High-Dose Conditioning Chemotherapy Comprising Busulfan, Melphalan, and Topotecan Hydrochloride Followed by Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed or Relapsed Solid Tumors
Phase:
No phase specified
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
6 months to 40
Sponsor:
NCI
Protocol IDs:
CHNMC-03112
, 03112, NCT00638898
Select All on Page
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
